Investment Thesis
NTHI exhibits critical financial distress with negative stockholders' equity of -$13.2M, technical insolvency, and a severe liquidity crisis (current ratio 0.13x). The company generates negligible revenue ($40K, down 51.8% YoY) while sustaining massive operating losses ($7.1M), resulting in negative free cash flow of -$7.5M and inadequate cash reserves ($138.6K). For a pharmaceutical company, the absence of meaningful revenue indicates no viable commercialized products, combined with mounting liabilities that exceed total assets by $13.3M.
Strengths
- Minimal cash position provides short-term buffer
- Active insider activity indicates potential strategic engagement
- Nasdaq listing provides access to capital markets if restructuring pursued
Risks
- Negative stockholders' equity of -$13.2M represents technical insolvency
- Current ratio of 0.13x signals acute liquidity crisis with liabilities 7.7x current assets
- Operating cash burn of -$7.0M per period with only $138.6K cash on hand
- Revenue collapse of 51.8% YoY with $40K quarterly revenue insufficient to support operations
- Total liabilities of $16.6M exceed total assets by $13.3M, indicating debt service capacity crisis
- No identifiable product revenue in pharmaceutical sector suggests absent commercialization strategy
Key Metrics to Watch
- Cash depletion timeline and whether operations cease within 2-3 months
- Restructuring or going-concern announcements in SEC filings
- Changes in revenue traction and operating cash burn rate
- Insider trading patterns and management retention
- Debt covenant compliance status and refinancing ability
Financial Metrics
Revenue
40.0K
Net Income
-8.8M
EPS (Diluted)
$-0.38
Free Cash Flow
-7.5M
Total Assets
3.3M
Cash
138.6K
Profitability Ratios
Gross Margin
N/A
Operating Margin
-17,643.6%
Net Margin
-22,055.3%
ROE
N/A
ROA
-264.9%
FCF Margin
-18,734.1%
Balance Sheet & Liquidity
Current Ratio
0.13x
Quick Ratio
0.13x
Debt/Equity
N/A
Debt/Assets
497.3%
Interest Coverage
-7.18x
Long-term Debt
320.0K
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-05-16T07:25:03.640405 |
Data as of: 2026-03-31 |
Powered by Claude AI